Treatment of anginose infectious mononucleosis with metronidazole. A controlled clinical and laboratory study.

Abstract

Metronidazole (600-1 200 mg daily) and phenoxymethyl penicillin (1.6 g daily) were administered to 21 patients with anginose type of infectious mononucleosis. A control group with 19 other patients received only phenoxymethyl penicillin in the same dosage. The patients were randomly allocated to metronidazole treatment and were stratified into 2 further groups according to the duration of tonsillitis (less than or equal to 5 and > days, respectively) before instituted therapy. Changes in the state of the tonsillitis, body temperature reaction and acute phase reactants (alfa1-antitrypsin, antichymotrypsin, C-reactive protein, haptoglobin and orosomucoid) were parameters for evaluation of the effect. Metronidazole treatment resulted in a more rapid regression of tonsillitis note on the 4th day in both treated groups and a faster defervescence noted on the 3rd day compared to controls. The effect was most pronounced in patients with a duration of tonsillitis for > 5 days at admission. At 2 weeks after start of treatment a more rapid normalization of acute phase reactants was seen in the metronidazole groups. Especially in patients with tonsillitis for > 5 days before treatment the decrease of the C-reactive protein level was rapid during the 1st week.

• Authors: S A Hedström
• Journal: Scandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 12 Issue 4 Pg. 265-9 ( 1980) ISSN: 0036-5548 [Print] England
• PMID: 6779371 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Review)

Chemical References

• Metronidazole
• C-Reactive Protein
• Penicillin V

Topics

• Adolescent
• Adult
• C-Reactive Protein (analysis)
• Clinical Trials as Topic
• Female
• Humans
• Infectious Mononucleosis (blood, drug therapy)
• Male
• Metronidazole (therapeutic use)
• Penicillin V (therapeutic use)
• Pilot Projects
• Tonsillitis (drug therapy)